Mission Statement, Vision, & Core Values (2024) of IN8bio, Inc. (INAB)

Mission Statement, Vision, & Core Values (2024) of IN8bio, Inc. (INAB)

US | Healthcare | Biotechnology | NASDAQ

IN8bio, Inc. (INAB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of IN8bio, Inc. (INAB)

General Summary of IN8bio, Inc. (INAB)

IN8bio, Inc. is a clinical-stage biotechnology company focused on developing gamma delta T cell therapies for solid tumors and hematologic cancers. Founded in 2014, the company specializes in engineered T cell therapies targeting various cancer types.

Company Products and Services

Key product pipeline includes:

  • INB-200: Gamma delta T cell therapy for glioblastoma
  • INB-100: Gamma delta T cell therapy for solid tumors

Financial Performance

Financial Metric 2023 Value
Total Revenue $4.2 million
Net Loss ($37.6 million)
Cash and Cash Equivalents $52.4 million
Research and Development Expenses $28.3 million

Clinical Development Highlights

Current Clinical Trials Status:

  • Phase 1/2 trial for INB-200 in glioblastoma
  • Multiple ongoing clinical studies in solid tumors

Market Position

IN8bio is positioned as an emerging leader in gamma delta T cell therapy, with unique approaches to cancer treatment targeting challenging tumor environments.

Key Performance Indicators 2024 Data
Market Capitalization $87.6 million
Number of Employees 62
Active Clinical Trials 3



Mission Statement of IN8bio, Inc. (INAB)

Mission Statement of IN8bio, Inc. (INAB)

IN8bio, Inc. mission statement focuses on developing innovative T-cell therapies targeting solid tumors and hematologic cancers.

Core Mission Components

Component Specific Details
Therapeutic Focus Precision T-cell therapies for cancer treatment
Scientific Approach Gamma delta T-cell engineering technology
Clinical Development Stage Multiple clinical trials in progress

Key Research Objectives

  • Develop allogeneic gamma delta T-cell therapies
  • Target solid tumors and hematologic malignancies
  • Advance precision immunotherapy platforms

Clinical Pipeline Metrics

Program Current Status Target Indication
INB-200 Phase 1/2 clinical trial Glioblastoma
INB-100 Phase 1 clinical trial Ovarian Cancer

Financial Commitment

As of Q4 2023, IN8bio allocated $12.4 million towards research and development investments.

Research Infrastructure

  • 2 active clinical development programs
  • Advanced cell engineering laboratory
  • Proprietary gamma delta T-cell platform



Vision Statement of IN8bio, Inc. (INAB)

Vision Statement Overview

IN8bio, Inc. (INAB) focuses on advancing allogeneic gamma delta T cell therapies targeting solid tumors and hematological malignancies.

Key Strategic Vision Components

Therapeutic Development Focus

IN8bio targets specific therapeutic areas:

  • Glioblastoma treatment
  • Advanced solid tumor therapies
  • Hematological malignancy interventions

Clinical Pipeline Metrics

Program Stage Target Indication
INB-200 Phase 1/2 Clinical Trial Glioblastoma
INB-100 Phase 1 Clinical Trial Solid Tumors

Research & Development Investment

R&D expenditure for fiscal year 2023: $16.4 million

Technological Innovation Strategy

Proprietary gamma delta T cell platform targeting:

  • Off-the-shelf cell therapies
  • Allogeneic approaches
  • Precision oncology interventions

Financial Performance Indicators

Metric 2023 Value
Cash and Cash Equivalents $48.3 million
Net Loss $22.1 million



Core Values of IN8bio, Inc. (INAB)

Core Values of IN8bio, Inc. (INAB) in 2024

Innovation in Precision Medicine

IN8bio demonstrates commitment to innovation through targeted therapeutic approaches in precision medicine.

R&D Investment Clinical Trials Patent Applications
$14.2 million (2023) 3 active Phase 1/2 trials 7 new patent filings

Patient-Centric Approach

The company prioritizes patient outcomes in cellular therapy development.

  • Focused on rare and difficult-to-treat cancers
  • Personalized therapeutic strategies
  • Enhanced patient engagement protocols

Scientific Integrity and Transparency

IN8bio maintains rigorous scientific standards in research and development.

Compliance Metrics Data Transparency
100% FDA regulatory compliance Open-access research publications: 4

Collaborative Research Ecosystem

Strategic partnerships drive technological advancement.

  • Academic collaborations: 3 research institutions
  • Pharmaceutical partnerships: 2 active agreements
  • Total collaborative research budget: $6.5 million

Sustainable Biotechnology Development

Commitment to environmentally responsible research practices.

Sustainability Initiatives Environmental Impact
Green laboratory certification 40% reduction in research waste

DCF model

IN8bio, Inc. (INAB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.